Back

Navigating the Landscape in CLL: Treatment Decisions, Patient Selection, and Sequencing Considerations

Navigating the Landscape in CLL: Treatment Decisions, Patient Selection, and Sequencing Considerations

In this OncLive News Network program, the panelists discussed the treatment landscape in chronic lymphocytic leukemia (CLL), including recent regulatory approvals and emerging strategies across frontline and relapsed/refractory disease. They compared covalent and noncovalent Bruton tyrosine kinase (BTK) inhibitors, weighed fixed-duration against continuous therapy, and considered when triplet regimens justify added toxicity. The panelists assessed the selective role of frontline pirtobrutinib and shared approaches to managing cardiovascular comorbidities, anticoagulation, and common adverse events. In relapsed disease, they reviewed venetoclax-based therapy and retreatment, the choice between pirtobrutinib and venetoclax after covalent BTK inhibitor progression, adding pirtobrutinib to venetoclax-rituximab, and pirtobrutinib bridging to chimeric antigen receptor T-cell therapy. They emphasized that sequencing no longer follows a single algorithm and that disease biology, comorbidities, logistics, and patient preference should guide the best feasible frontline regimen. The panelists closed by identifying knowledge gaps, including therapy after frontline pirtobrutinib, comparative BTK inhibitor data, and emerging sonrotoclax combinations.

Navigating the Landscape in CLL: Treatment Decisions, Patient Selection, and Sequencing Considerations

Episodes

All
All